

IN THE CLAIMS

Please amend the claims as follows:

1-38 (Cancelled)

39. (New) A method for producing a pre-metered dry powder combined dose of finely divided dry medication powders, comprising:

separately depositing pre-metered, medicinally effective quantities of each of first and second dry powder medicaments onto selected target areas of a common dose bed, the first dry powder medicament comprising at least one bronchodilating medicament and the second dry powder medicament comprising at least one anti-inflammatory medicament, where the sum of the pre-metered separately deposited medicaments constitutes a pre-metered quantity of powder of the dry powder combined dose; and

sealing the dry powder combined dose on the common dose bed from ingress of moisture by at least one protective foil to form a sealed dry powder combined dose,

wherein the sealed dry powder combined dose is designed to be introduced into a dry powder inhaler device for delivery of the dry powder combined dose during the course of a single inhalation by a user, wherein the delivered dry powder combined dose, when delivered, comprises de-aggregated fine particles of the first and second medicaments.

40. (New) The method according to claim 39, wherein the first medicament comprises formoterol or a pharmaceutically acceptable salt, enantiomer, racemate, hydrate, or solvate thereof, or mixtures thereof and the second medicament comprises budesonide or a pharmaceutically acceptable salt, enantiomer, racemate, hydrate, or solvate thereof, or mixtures thereof.

41. (New) The method according to claim 39, wherein the first medicament comprises formoterol or a pharmaceutically acceptable salt, enantiomer, racemate, hydrate, or solvate thereof, or mixtures thereof and the second medicament comprises fluticasone or a pharmaceutically acceptable salt, enantiomer, racemate, hydrate, or solvate thereof, or mixtures thereof.

42. (New) The method according to claim 39, wherein the first medicament comprises formoterol or a pharmaceutically acceptable salt, enantiomer, racemate, hydrate, or solvate

thereof, or mixtures thereof and the second medicament comprises mometasone or a pharmaceutically acceptable salt, enantiomer, racemate, hydrate, or solvate thereof, or mixtures thereof.

43. (New) The method according to claim 39, wherein the first medicament comprises formoterol or a pharmaceutically acceptable salt, enantiomer, racemate, hydrate, or solvate thereof, or mixtures thereof and the second medicament comprises ciclesonide or a pharmaceutically acceptable salt, enantiomer, racemate, hydrate, or solvate thereof, or mixtures thereof.

44. (New) The method according to claim 39, wherein the first medicament comprises one or more of Albuterol, Bambuterol, Bitolterol, Broxaterol, Carbuterol, Clenbuterol, Etanterol, Fenoterol, Formoterol, Hexoprenaline, Imoxiterol, Isoetharine, Metaproterenol, Naminterol, Picumeterol, Pirbuterol, Procaterol, Rimiterol, Reproterol, Salmeterol, Terbutaline, Tiotropium, Tulobuterol, pharmaceutically acceptable salts, enantiomers, racemates hydrates, or solvate thereof, or mixtures thereof and the second medicament comprises one or more of Budesonide, Beclomethasone, Ciclesonide, Dexametasone, Flunisolide, Fluticasone, Ipratropium, Mometasone, Triamcinolone, pharmaceutically acceptable salts, enantiomers, racemates hydrates, or solvate thereof, or mixtures thereof.

45. (New) The method according to claim 39, wherein the dry powder combined dose has a total mass of 10  $\mu$ g to 50 mg.

46. (New) The method according to claim 39, further comprising depositing a biologically acceptable, inert substance between the deposits of the medicaments to separate the deposits of the medicaments from each other onto the dose bed, such that the medicaments cannot detrimentally mix with each other after forming of the combined dose.

47. (New) The method according to claim 39, further comprising administering said combined dose via a continuous dry powder inhaler (DPI) designed for a prolonged delivery of the medicinal combined dose to a user inhaling once through the DPI.

48. (New) The method according to claim 39, wherein said at least one protective foil is designed to be opened by a foil cutting arrangement of said dry powder inhaler device.

49. (New) A pharmaceutical dry powder combined dose product, adapted for inhalation using a dry powder inhaler device, for the treatment of a respiratory disorder in a mammalian host, comprising:

at least one first medicament selected from a group of bronchodilating medicaments;

at least one second medicament selected from a group of anti-inflammatory medicaments;

a common dose bed onto which pre-metered medicinally effective quantities of the first and second medicaments are separately deposited, where the sum of the deposits constitute the pre-metered quantity of powder in the dry powder combined dose product; and

at least one protective foil forming a seal that protects the dry powder combined dose on the common dose bed from ingress of moisture to form a sealed dry powder combined dose,

wherein the sealed dry powder combined dose is designed for insertion into a dry powder inhaler device where the pre-metered quantities of the selected medicaments become delivered from the dry powder inhaler device during a single inhalation when suction is applied through the dry powder inhaler device.

50. (New) The pharmaceutical dry powder combined dose product according to claim 49, wherein the first medicament comprises formoterol or a pharmaceutically acceptable salt, enantiomer, racemate, hydrate, or solvate thereof, or mixtures thereof and the second medicament comprises budesonide or a pharmaceutically acceptable salt, enantiomer, racemate, hydrate, or solvate thereof, or mixtures thereof.

51. (New) The pharmaceutical dry powder combined dose product according to claim 49, wherein the first medicament comprises formoterol or a pharmaceutically acceptable salt, enantiomer, racemate, hydrate, or solvate thereof, or mixtures thereof and the second medicament comprises fluticasone or a pharmaceutically acceptable salt, enantiomer, racemate, hydrate, or solvate thereof, or mixtures thereof.

52. (New) The pharmaceutical dry powder combined dose product according to claim 49, wherein the first medicament comprises formoterol or a pharmaceutically acceptable salt, enantiomer, racemate, hydrate, or solvate thereof, or mixtures thereof and the second medicament comprises mometasone or a pharmaceutically acceptable salt, enantiomer, racemate, hydrate, or solvate thereof, or mixtures thereof.

53. The pharmaceutical dry powder combined dose product according to claim 49, wherein the first medicament comprises formoterol or a pharmaceutically acceptable salt, enantiomer, racemate, hydrate, or solvate thereof, or mixtures thereof and the second medicament comprises ciclesonide or a pharmaceutically acceptable salt, enantiomer, racemate, hydrate, or solvate thereof, or mixtures thereof.

54. (New) The pharmaceutical dry powder combined dose product according to claim 49, wherein the first medicament comprises one or more of Albuterol, Bambuterol, Bitolterol, Broxaterol, Carbuterol, Clenbuterol, Etanterol, Fenoterol, Formoterol, Hexoprenaline, Imoxiterol, Isoetharine, Metaproterenol, Naminterol, Picumeterol, Pirbuterol, Procaterol, Rimiterol, Reproterol, Salmeterol, Terbutaline, Tiotropium, Tulobuterol, pharmaceutically acceptable salts, enantiomers, racemates hydrates, or solvate thereof, or mixtures thereof and the second medicament comprises one or more of Budesonide, Beclomethasone, Ciclesonide, Dexametasone, Flunisolide, Fluticasone, Ipratropium, Mometasone, Triamcinolone, pharmaceutically acceptable salts, enantiomers, racemates hydrates, or solvate thereof, or mixtures thereof.

55. (New) The pharmaceutical dry powder combined dose product according to claim 49, wherein the combined dose has a total mass in a range from 10  $\mu$ g to 50 mg.

56. (New) The pharmaceutical dry powder combined dose product according to claim 49, wherein the pre-metered medicaments are deposited onto the common dose bed to form a medicinal combined dose having a general elongated shape.

57. (New) The pharmaceutical dry powder combined dose product according to claim 49, wherein each of the pre-metered medicaments is deposited in a respective separate compartment of the common dose bed.

58. (New) The pharmaceutical dry powder combined dose product according to claim 49, wherein a biologically acceptable, inert substance is deposited between the deposits of the medicaments to prevent the medicaments from interacting detrimentally after forming of the combined dose.

59. (New) The pharmaceutical dry powder combined dose product according to claim 49, wherein the medicinal combined dose is adapted for delivery from a dry powder inhaler device during the course of a single inhalation by gradual aerosolization of the combined dose in the form of a relative motion between an air-sucking nozzle and the common dose bed.

60. (New) The pharmaceutical dry powder combined dose product according to claim 49, wherein the at least one protective foil is designed to be opened by a foil cutting arrangement of the dry powder inhaler device.